WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Kürzel: WX8 Forum: Aktien User: Summer.76

Consun Pharmaceutical (01681) und WuXi AppTec (02359) sind eine strategische Kooperation eingegangen https://wap.eastmoney.com/a/202107192002870128.html

Morgan Stanley: WuXi AppTec (2359 HK) results forecast to beat market expectations and raise target price to HK$200 https://m.jrj.com.cn/madapter/hk/2021/07/16105333106312.shtml According to a research report published by Morgan Stanley, WuXi AppTec (2359 HK)'s initial earnings for the first half of the year beat market expectations. The bank has raised the company's 2021-2024 earnings forecast by 6% to 10%, and its estimates reflect clinical testing services. And the impact of the increase in CDMO/CMO revenue, the expansion of gross profit margin and the decrease in cost-to-expense ratio, the company’s H-share target price was raised from HK$178 to HK$200, and the rating was increased. At the same time, the target under the basic scenario, the bullish and bearish scenario The price rose by 12% to 13%.

WUXI APPTEC Expects 1H NP to Soar Over RMB900M http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1113078/hk-stock-news WUXI APPTEC (02359 HK) issued a positive profit alert. The net profit attributable to shareholders of the Company was estimated to increase by a range between RMB910 million to RMB944 million for the first half of 2021, as compared with RMB1.717 billion for the first half of 2020, representing a year-over-year increase of a range between 53% to 55%. Im folgenden Artikel noch etwas ausführlicher (Übersetzer nötig): https://www.finet.hk/newscenter/news_content/60f0ee58bde0b337360b8b08

20 ✌️

Die Gründe etwas ausführlicher: CRO stocks plummeted and worries that the new policy reduces the number of orders https://m.hkej.com/landing/mobarticle2/id/2845856/%E3%80%90%E7%95%B0%E5%8B%95%E6%9D%BF%E5%A1%8A%E3%80%91CRO%E8%82%A1%E6%80%A5%E6%8C%AB+%E6%86%82%E6%96%B0%E6%94%BF%E4%BB%A4%E8%A8%82%E5%96%AE%E6%95%B8%E9%87%8F%E9%99%8D

Es fiel noch deutlich tiefer als zum Zeitpunkt des Schreibens 📉: Hong Kong stocks move | WuXi Biologics (02269) fell over 5% and led the decline in CRO concept stock CDE publicly solicits opinions on guiding principles for the development of innovative anti-tumor drugs https://finance.sina.cn/hkstock/ggyw/2021-07-06/detail-ikqcfnca5193370.d.html?from=wap Pharmaceutical outsourcing stocks fell across the board, as of this writing, medicine WuXi biologics (02269) fell 6.38 percent to HK $ 129.2; Tiger medicine (03347) fell 4.12 percent to HK $ 170; into Hong Long (03759) fell 2.75%, report 187.6 Hong Kong dollars; WuXi AppTec (02359) fell 2.4% to 170.8 Hong Kong dollars. On the news, on July 2, the Center for Drug Evaluation (CDE) of the National Medical Products Administration issued the "Notice on the Public Solicitation of Opinions on the Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented by Clinical Value". The market tends to believe that the changes in the BSC selected for clinical controlled trials in the draft opinion will affect the prosperity of CXO in the future. Because this change will directly reduce the possibility of drugs developed using the me-too method on the market in the future, which will affect the number of new drug companies' products and reduce the number of orders that CXO companies can obtain.

Shanghai lief ja heute positiv. Morgen ist dann auch wieder HK am Start.

WuXi AppTec (02359) subsidiary plans to subscribe for a private equity fund of US$30 million https://m.jrj.com.cn/madapter/hk/2021/07/01205933029291.shtml

WuXi AppTec (02359 HK) has been increased by JPMorgan Chase’s holdings of 3.279931 shares https://m.jrj.com.cn/madapter/hk/2021/06/29175833016733.shtml According to the equity information of the Hong Kong Stock Exchange, WuXi AppTec (02359 HK) was acquired by JPMorgan Chase on June 24 at an average price of HK$175.4562 per share to increase its holdings of 3,279,900 shares, involving approximately HK$575 million. . After the increase, JPMorgan Chase’s latest shareholding number was 20.9155 million shares, and the shareholding ratio increased from 4.57% to 5.42%.

China-based WuXi AppTec wins $19M from taxpayers for giant Delaware drug plant https://www.inquirer.com/business/wuxi-apptec-delaware-drug-factory-pharmaceutical-20210628.html Delaware has voted up to $19 million in "capital development" and jobs grants and may add $2 million for roads for Shanghai-based WuXi AppTec, which employs 600 in Philly.

Donnerstag ist Feiertag in HK

http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1108672/hk-stock-news WUXI APPTEC Mulls Dumping JW THERAP-B Shrs at Up to 8% Discount, Pockets About $670M: Report

Die AppTec scheint Geld einzusammeln, indem sie wohl bei der JW Therap. (= WuXi Giant Nuo) reduziert: https://inews.hket.com/article/2993162/%E3%80%90%E9%85%8D%E8%82%A1%E6%BD%AE%E3%80%91%E8%97%A5%E6%98%8E%E5%BA%B7%E5%BE%B7%E6%8A%98%E8%AE%93%E6%9C%80%E5%A4%9A8-%E9%85%8D%E5%94%AE%E8%97%A5%E6%98%8E%E5%B7%A8%E8%AB%BE%E3%80%80%E5%A5%97%E7%8F%BE6.7%E5%84%84%E5%85%83 Bloomberg quoted a sales document showing that WuXi AppTec (02359) intends to place 23 million shares of WuXi Giant Nuo (02126) at a price ranging from 28.5 to 29.15 yuan, which is a discount of 31 yuan from the closing price of WuXi Giant Nuo on Monday.  Let 6% to 8.1%, cash out up to 670 million yuan.  WuXi AppTec has a 3-month lock-up period and arranges for Morgan Stanley.

Handel an der HKEX startete gerade erst (nach Aussetzung wg Sturm/ Regen).

WuXi AppTec (02359 HK): 8,26 Millionen gesperrte A-Aktien werden aus den Verkaufsbeschränkungen aufgehoben https://m.jrj.com.cn/madapter/hk/2021/06/25223632998767.shtml WuXi AppTec (02359 HK) wird 480.000 gesperrte A-Aktien zurückkaufen https://m.jrj.com.cn/madapter/hk/2021/06/25223232998754.shtml